• Revenue reached $18.4 million, up 41% year-on-year
• EBITDA* (excluding share based payments) was $931,050 for the full year
• Domestic sell-through increased 50%+, establishing market leadership

Biome Australia Limited reported its first profitable year since inception in 2018, with net profit of $214,656 achieved alongside strong operational metrics. Revenue reached $18.4 million, up 41% year-on-year, significantly outperforming category growth rates by 7-10 times. EBITDA* (excluding share based payments) was $931,050 for the full year, marking the sixth consecutive quarter of positive EBITDA. Gross margin held steady at 61%. Q4 delivered $5 million in revenue with June posting a record monthly result of $2.1 million. Activated Probiotics secured the number two position in total probiotic revenue within community pharmacy. Domestic sell-through increased 50%+, establishing market leadership in category growth without relying on discount strategies. International revenue hit $1.5 million, up 69% year-over-year, with distribution agreements secured across four markets: Canada, Ireland, UK, and New Zealand. The company launched its Activated Therapeutics practitioner-only range with four products targeting specific therapeutic areas and completed a proprietary strain development program, securing IP ownership of Lactobacillus plantarum BMB18.

Current performance trajectory supports Vision 27 target of $75 million cumulative sales for FY25-27. Strong cash position and positive cash flow provide foundation for continued expansion without immediate capital requirements.

The company has a strong cash position of $2.7 million and a further $2.1 million in an undrawn credit facility, providing a solid foundation for continued expansion and growth.